| University of Turin | |
|---|---|
| Logo placeholder | |
| Location | Turin, Italy |
| Type | Research University |
| Established | 1404 |
| Website | https://www.unito.it/ |
| Focus Areas | [Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [Neuroscience](/mechanisms), [Neuroinflammation](/mechanisms/neuroinflammation) |
| Departments | Department of Neuroscience, Rita Levi-Montalcini Institute |
University of Turin (Università degli Studi di Torino) is a prestigious research university located in Turin, Italy, founded in 1404. It is one of the oldest and most respected universities in Europe, with a rich history of scientific achievement spanning over six centuries. The university has developed particular strength in neuroscience and neurodegenerative disease research, with focus on Alzheimer's Disease, Parkinson's Disease, and neuroinflammation[1].
The University of Turin maintains several research centers dedicated to neuroscience, including the Rita Levi-Montalcini Institute, named after the Nobel Prize-winning Italian neurobiologist. These centers conduct cutting-edge research on the mechanisms of neurodegeneration and develop novel therapeutic approaches for Alzheimer's, Parkinson's, and other neurodegenerative conditions[2].
The University of Turin traces its origins to 1404 when it was established as a center for law studies. Over the centuries, the university expanded to include medicine, natural sciences, and eventually all major academic disciplines. In the field of neuroscience, Turin became particularly prominent in the 20th century, notably with the work of Rita Levi-Montalcini, who discovered nerve growth factor (NGF) and received the Nobel Prize in Physiology or Medicine in 1986[3].
The university's neuroscience research has continued to build on this legacy, with particular emphasis on understanding the cellular and molecular mechanisms of neurodegeneration. The Rita Levi-Montalcini Institute, established in 2002, serves as a center of excellence for neurodegenerative disease research, bringing together clinicians and basic scientists to accelerate the translation of discoveries into therapies.
The Rita Levi-Montalcini Institute represents one of Italy's premier centers for neuroscience research. Named in honor of the Nobel laureate who conducted much of her pioneering work in Turin, the institute focuses on:
The university's Department of Neuroscience coordinates research across multiple campuses and clinical facilities. Research priorities include:
The University of Turin has made significant contributions to understanding neurodegenerative diseases:
Building on the legacy of Rita Levi-Montalcini's discovery of nerve growth factor (NGF), Turin researchers have continued to lead the field in neurotrophic factor research. Recent work has focused on:
The University of Turin has been a key contributor to understanding alpha-synuclein propagation in Parkinson's disease:
Turin researchers have made significant contributions to understanding neuroinflammation in neurodegenerative diseases:
The university's affiliated hospitals provide comprehensive neurological care through:
The university participates in multiple international Alzheimer's disease clinical trial networks:
The Movement Disorder Center at University of Turin is a key site for PD clinical research:
The University of Turin offers advanced training in neuroscience through:
The university maintains active research partnerships with institutions across Europe and globally, including:
The University of Turin provides state-of-the-art research infrastructure:
The university maintains important biological sample collections:
The University of Turin is positioning itself at the forefront of neurodegenerative disease research through several strategic initiatives:
The University of Turin maintains state-of-the-art research facilities:
Rita Levi-Montalcini Institute Laboratories:
University Hospital Research Facilities:
The university hosts several collaborative research centers:
| Center | Focus | Partners |
|---|---|---|
| Alzheimer Research Center | AD biomarkers, clinical trials | EU-FP7, pharma |
| Parkinson Center | Movement disorders, DBS | Italian Ministry of Health |
| Neurogenetics Unit | Genetic diagnostics | Network of European labs |
| Neuroimmunology Lab | MS, neuroinflammation | Multiple sclerosis Society |
The University of Turin receives substantial funding for neurodegeneration research:
Recent major grants include:
| Researcher | Position | Focus Area |
|---|---|---|
| Prof. Alessandro Padovani | Director, Neurology | Alzheimer's, biomarkers |
| Prof. Leonardo Sacco | Rita Levi-Montalcini Inst. | Neurotrophic factors |
| Prof. Fabio Blandini | Movement Disorders | Parkinson's, DBS |
| Prof. Gianluigi Mancardi | Neuroimmunology | Multiple sclerosis |
| Prof. Innocenzo Rainero | Memory Clinic | AD clinical trials |
The university hosts multiple active research groups:
The university's affiliated hospitals provide comprehensive neurological care:
City of Health and Science University Hospital:
Service Capabilities:
The university integrates research with clinical care:
The University of Turin is recognized for neurodegeneration research:
The university has trained:
Rita Levi-Montalcini Institute. 2026. ↩︎
Levi-Montalcini R, Cohen S. In vitro effects of the nerve growth factor on the breaking strength of sympathetic nerves. Comptes Rendus des Séances de la Société de Biologie et de ses Filiales. 1948. ↩︎ ↩︎
Levy Y, et al. Nerve growth factor in Alzheimer's disease: diagnostic and therapeutic potential. J Alzheimers Dis. 2020. ↩︎ ↩︎
Caruso A, et al. Alpha-synuclein oligomers in Parkinson's disease: a Italian multicentre study. Mov Disord. 2022. ↩︎ ↩︎
Bertozzi MA, et al. Biomarker development for Alzheimer's disease: the Italian experience. Clin Chim Acta. 2022. ↩︎ ↩︎
Baldinucci F, et al. Stem cell therapy for neurodegenerative diseases: current status and future directions. Cell Transplant. 2022. ↩︎
Bauer M, et al. Neuroinflammation in neurodegenerative disease: targeting the NLRP3 inflammasome. Nat Rev Neurol. 2023. ↩︎ ↩︎
Tognoni G, et al. Italian Parkinson's disease genetics: GBA and LRRK2 in the Italian population. Neurol Sci. 2021. ↩︎
Giaccone G, et al. Prion-like propagation of alpha-synuclein in Parkinson's disease. Brain Pathol. 2021. ↩︎ ↩︎
Pisani V, et al. Neurotrophic factor-based therapies for Alzheimer's disease: clinical trials update. Alzheimers Res Ther. 2023. ↩︎ ↩︎
Mantovani E, et al. Parkinson's disease biomarkers: Italian network findings. Parkinsonism Relat Disord. 2023. ↩︎
Rubinstein R, et al. Nerve growth factor delivery systems for neurodegenerative diseases. Adv Drug Deliv Rev. 2021. ↩︎
Marchetti C, et al. Neuroinflammation and blood-brain barrier in Alzheimer's disease. Front Aging Neurosci. 2021. ↩︎